抄録
The availability of CYFRA21-1 levels as a tumor marker in patient sera, was examined in this study for the diagnosis and prognosis of malignant head and neck disease, and was compared with that of established squamous cell carcinoma (SCC) antigen. CYFRA21-1 was determined to be useful as a tumor marker, similar to SCC antigen, and CYFRA21-1 was superior to SCC antigen as a diagnostic factor in patients with even early stages of malignant disease. Serum levels of CYFRA21-1 appeared to accurately reflect the clinical course of head and neck cancer patients. However, our study is ongoing and a more extensive and precise evaluation of this important issue, is required.
© 耳鼻咽喉科臨学会